The purpose of the study is to determine the appropriate dose of lutetium Lu 177 edotreotide for children, based on its safety and how it moves through the body. The study will involve giving the treatment to participants and monitoring them to see how their bodies respond. This includes checking for any side effects and measuring how the treatment is absorbed by the body. The study will also look at how effective the treatment is in reducing the size of the tumors.

Participants in the study will receive the treatment through an intravenous infusion, which means it will be given directly into a vein. The study will take place over several cycles, with regular check-ups to monitor the participants’ health and the progress of the treatment. The goal is to find the safest and most effective dose for treating these types of tumors in children. The study is expected to continue for several years to gather enough information to make informed decisions about the treatment’s use in the future.

The study is divided into three parts. In Part A, patients with advanced solid tumors or lymphomas will receive OSE-279 to determine the best dose. In Part B, the safety and tolerability of the combination of OSE-279 and TEDOPI will be evaluated in patients with metastatic Non-Small Cell Lung Cancer (NSCLC) who have a specific genetic marker called HLA-A2. In Part C, the effectiveness of the combination treatment will be compared to OSE-279 alone in patients with the same type of lung cancer. The study will involve regular visits to the clinic for treatment and monitoring over a period of time.

Throughout the study, patients will receive either the study medications or a placebo. The study aims to assess how well the treatments work in terms of reducing the size of the tumors and improving the overall response rate. The study will also monitor any side effects experienced by the participants to ensure the treatments are safe. The trial is expected to continue until 2029, with the goal of finding new and effective treatment options for these types of cancer.

Participants in the study will receive Valemetostat Tosylate as a monotherapy, meaning it is the only treatment they will be given. The study will follow a single-arm design, which means all participants will receive the same treatment without a comparison group. The medication will be administered orally, and the study will monitor the participants over a period of time to observe their response to the treatment and any side effects they may experience. The study aims to gather information on the effectiveness of the treatment in reducing the cancer and improving the patients’ condition.

Throughout the study, participants will undergo regular assessments to check their health status and the progress of the treatment. These assessments may include medical tests and imaging techniques like computed tomography (CT) scans to measure the size of the cancer. The study will also track any adverse effects or changes in the participants’ health to ensure the treatment is safe. The ultimate goal is to determine if Valemetostat Tosylate can be a beneficial treatment option for patients with relapsed or refractory Peripheral T-Cell Lymphoma.

The purpose of this study is to assess how well the R-Hyper-CVAD/R-MA treatment works in patients with high-risk aggressive B-cell lymphomas. Participants in the study will receive the treatment over a period of time, with regular monitoring to track their response to the therapy. The study will also compare the outcomes of patients receiving the treatment with those who might receive a placebo. The trial will look at several outcomes, including how long patients live without the cancer getting worse, overall survival rates, and the response of the cancer to the treatment.

Throughout the study, participants will be closely monitored by healthcare professionals to ensure their safety and to manage any side effects that may occur. The trial is designed to provide valuable information about the effectiveness of the R-Hyper-CVAD/R-MA treatment regimen in managing aggressive B-cell lymphomas, potentially leading to improved treatment options for patients with this type of cancer.

The purpose of this study is to determine the best dose of CPI-0209 and to evaluate its effectiveness in treating these advanced cancers. The study is divided into two phases. In the first phase, researchers aim to find the maximum dose that patients can tolerate. In the second phase, the focus is on assessing how well CPI-0209 works in shrinking or controlling the tumors. Patients participating in the study will receive either CPI-0209 or a placebo, and their health will be monitored closely throughout the trial.

Participants in the study will undergo regular health assessments, including blood tests and imaging scans, to track the progress of their treatment. The study will help researchers understand the potential benefits and side effects of CPI-0209, contributing to the development of new treatment options for patients with these challenging types of cancer. The trial is expected to continue until 2025, providing valuable insights into the treatment of advanced solid tumors and lymphomas.

The purpose of the study is to determine if a single dose of Heparin given before collecting stem cells can increase the number of stem cells collected. Participants in the study will receive either Heparin or a placebo before their stem cell collection. The study will monitor the number of stem cells collected and assess the safety of using Heparin in this way. The trial will involve regular blood tests to track the increase of stem cells in the blood during the collection process.

The study will also evaluate any potential side effects related to the use of Heparin, such as bleeding complications. This will be done by reviewing medical records after the stem cell collection is completed. Additionally, some of the collected stem cells will be analyzed using advanced techniques to better understand their characteristics. The trial aims to provide valuable information that could improve the process of stem cell collection for patients with lymphoma and myeloma.